Drug delivery system targeting MM cells
A biocompatible and biodegradable delivery vehicle decorated with anti-CD38 monoclonal antibodies for the treatment of MM. This vehicle safely encapsulates Bortezomib (or other chemotherapy), while it targets the cell-surface CD38 receptor present on MM cells. The studies reveal selective release of the drug in MM cells. Subsequent endosomal transport to the proteasome enables its inhibition of processes crucial for MM cell survival. This approach limits side effects, is poised to maximize treatment tolerance, and hence, increase treatment success. The platform technology is also amenable to other (chemo) therapeutics and cell-targeting strategies.